ESTA Share Price Performance
US$62.06
31.92 (105.91%)
30.3% undervalued intrinsic discount
US$89.00
Fair Value
Price US$62.06
AnalystConsensusTarget US$89.00
AnalystLowTarget US$75.00
AnalystHighTarget US$100.00
Fair ValueUS$89.00
Share Pricen/a
Establishment Labs Holdings Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
ESTA Community Narratives
AN
Fair Value US$89 30.3% undervalued intrinsic discount
Surgeon Adoption And Patient Demand Will Expand Markets
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$75 17.3% undervalued intrinsic discount
Regulatory And Cultural Headwinds Will Curb Cosmetic Procedures Despite Gains
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$100 37.9% undervalued intrinsic discount
Rising Middle Class Will Drive Global Aesthetic Trends
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Surgeon Adoption And Patient Demand Will Expand Markets
Key Takeaways Strong U.S. adoption and innovative product launches are boosting revenue growth, market share, and margins in an expanding and affluent market. International expansion and operational improvements support diversified, long-term growth while limiting geographic risk and enhancing profit scalability.Read more
78
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$89
30.3% undervalued intrinsic discount
Fair Value
Profit Margin
11.15%
Future PE
72.59x
Price in 2029
US$110.06
Rising Middle Class Will Drive Global Aesthetic Trends
Key Takeaways Surging patient-driven demand and innovative procedures are accelerating market adoption, premium pricing, and recurring revenue beyond analyst expectations, especially in the U.S. Operational improvements and strong international presence underpin rapid earnings growth, margin expansion, and a durable competitive advantage as industry standards evolve. Regulatory scrutiny, demographic shifts, cash burn, and reliance on silicone implants expose Establishment Labs to revenue and profit risks amid rising competition from non-invasive alternatives.Read more
12
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$100
37.9% undervalued intrinsic discount
Fair Value
Profit Margin
15.09%
Future PE
63.96x
Price in 2029
US$136.29
Regulatory And Cultural Headwinds Will Curb Cosmetic Procedures Despite Gains
Key Takeaways Shifts in societal attitudes and regulatory pressures threaten core product demand and acceptance, potentially limiting revenue growth and adding compliance costs. Heavy investment and market concentration risk strain profitability, with intensifying competition and evolving technologies threatening margins and market share.Read more
14
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$75
17.3% undervalued intrinsic discount
Fair Value
Profit Margin
10.64%
Future PE
75.6x
Price in 2029
US$105.39
Trending Discussion
Recently Updated Narratives
AN
ESTA: Sustained EBITDA Profitability And 2026 Guidance Will Support Stronger Outlook
Fair Value: US$89 30.3% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ESTA: Sustained Adj EBITDA Profitability And US Guidance Will Drive Repricing
Fair Value: US$100 37.9% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ESTA: Q3 Profitability And U.S. Expansion Will Reshape Earnings Profile
Fair Value: US$75 17.3% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Establishment Labs Holdings Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -1.74
- 69.32%
- -24.19%
- 1,103.9%
About ESTA
- Founded
- 2004
- Employees
- 1004
- CEO
- WebsiteView website
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for breast aesthetic and reconstructive plastic surgeries in Europe, the Middle East, Africa, Latin America, Asia, and the United States. The company offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides breast tissue expanders. The company sells products to physicians, hospitals, and clinics through distributors and its direct sales force. Establishment Labs Holdings Inc. was incorporated in 2004 and is based in Austin, Texas.
